CAS NO: | 915759-45-4 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | WAY 316606 is an inhibitor of the secreted proteinsFRP-1, an endogenous antagonist of the secretedglycoproteinWnt. The affinity of WAY-316606 forsFRP-1is determined using theFPbinding assay withIC50of 0.5 μM[1]. | ||||||||||||||||
IC50& Target | IC50: 0.5 μM (sFRP-1)[1] | ||||||||||||||||
体外研究 (In Vitro) | The EC50of WAY-316606 for Wnt-Luciferase Activity from U2-OS Cells is 0.65 μM[1]. WAY-316606 binds to secreted frizzled-related protein (sFRP)-1 inhibitor with a KDof 0.08 μM and inhibits sFRP-1 with an EC50of 0.65 μM. WAY-316606 also binds to sFRP-2, albeit over 10 times weaker with a KDof 1 μM. Using a fluorescence polarization binding assay that employs a fluorescent probe compound and purified human sFRP-1 protein in a competitive-binding format, the IC50for WAY-316606 is 0.5 μM[2]. | ||||||||||||||||
体内研究 (In Vivo) | WAY-316606 increases bone formation when tested in a neonatal murine calvarial assay. WAY-316606 increases total bone area up to 60% in a dose-dependent manner with an EC50of about 1 nM. WAY-316606 has good aqueous solubility, moderate to low inhibition of cytochrome p450 isozymes (3A4, 2D6, 2C9) and good stability in rat and human liver microsomes (t1/2>60 min in each species). In female Sprague-Dawley rats, WAY-316606 exhibits high plasma clearance (77 mL/min/kg, greater than hepatic blood flow) following a single intravenous bolus dose (2 mg/kg), which results in a rapid decline of drug exposure in the plasma despite the route of administration[2]. | ||||||||||||||||
分子量 | 448.48 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C18H19F3N2O4S2 | ||||||||||||||||
CAS 号 | 915759-45-4 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(222.98 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |